A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
formats

Boston Scientific’s Q2 2013 AIMD Results: CRM Down 3%, Neuromodulation Up 21%

Today Boston Scientific announced its Q2 2013 results.  CRM sales were 3% down from $488M for Q2 2012 to $475M this year (2% on constant-currency basis). Neuromodulation went up by a whopping 21% from last year’s Q2 $91M to $111 in Q2 2013.  The press release indicated that Boston Scientific achieved global year-over-year revenue growth

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific’s Q2 2013 AIMD Results: CRM Down 3%, Neuromodulation Up 21%  comments